Ending the HIV epidemic among persons who inject drugs: A cost-effectiveness analysis in six US cities

Localized HIV Modeling Study Group

Research output: Contribution to journalArticlepeer-review


Background. Persons who inject drugs (PWID) are at a disproportionately high risk of HIV infection. We aimed to determine the highest-valued combination implementation strategies to reduce the burden of HIV among PWID in 6 US cities. Methods. Using a dynamic HIV transmission model calibrated for Atlanta, Baltimore, Los Angeles, Miami, New York City, and Seattle, we assessed the value of implementing combinations of evidence-based interventions at optimistic (drawn from best available evidence) or ideal (90% coverage) scale-up. We estimated reduction in HIV incidence among PWID, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) for each city (10-year implementation; 20-year horizon; 2018 $ US). Results. Combinations that maximized health benefits contained between 6 (Atlanta and Seattle) and 12 (Miami) interventions with ICER values ranging from $94 069/QALY in Los Angeles to $146 256/QALY in Miami. These strategies reduced HIV incidence by 8.1% (credible interval [CI], 2.8%-13.2%) in Seattle and 54.4% (CI, 37.6%-73.9%) in Miami. Incidence reduction reached 16.1%-75.5% at ideal scale. Conclusions. Evidence-based interventions targeted to PWID can deliver considerable value; however, ending the HIV epidemic among PWID will require innovative implementation strategies and supporting programs to reduce social and structural barriers to care.

Original languageEnglish (US)
Pages (from-to)S301-S311
JournalJournal of Infectious Diseases
Issue numberSupplement_5
StatePublished - Oct 1 2020


  • Cost-effectiveness
  • Dynamic HIV transmission model
  • HIV
  • Injection drug use
  • Interventions
  • Localized HIV microepidemics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Ending the HIV epidemic among persons who inject drugs: A cost-effectiveness analysis in six US cities'. Together they form a unique fingerprint.

Cite this